52 Live Notices for Erythropoietin Tenders
Showing 1 to 20
Delivery Of Pharmacological Group B Drugs - "Blood And Hematopo -Bodies" For The Needs Of The Multidisciplinary Hospital For Active Treatment "Ivan Skenderov" Eood For A Period Of Two Years In 18 Lots - Second Part
13 Mar 2025
14 Apr 2025Erythropoietin Agreement
"Delivery Of Medicinal Products Needed For The Activity Of" Complex Oncology Center - Plovdiv "Eood, Intended For The Treatment Of Oncological Diseases"
Shopping For Dialysis While Waiting For Spacious Bidding At Duy Tien Town Medical Center In 2025
Supply, Installation, Testing And Commissioning Of Cold Room Facilities And Accessories Tools For 10 Pig Slaughterhouses On Behalf Of Prism Project
Antipsychotic Substances, Dermatological Preparations, Preparations To Relieve Cough And Cold, Anti -Anemia Preparations, Peripheral Muscle Relaxing Substances 2
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V For The Active Ingredient Erythropoietin, Excluding Epoetin Alfa, (Obo) Atc B03Xa01 For The Period 01.03.2025 - 28.02.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V For The Active Ingredient Erythropoietin, Excluding Epoetin Alfa, (Obo) Atc B03Xa01 For The Period 01.03.2025 - 28.02.2027
Securing Drug Items For The E-Market Platform
Conclusion Of Non-Exclusive Discount Agreements According To §130A Para.8 Sgb V For Various Active Ingredients/Combinations With The Possibility Of Conclusion At Any Time Within The Framework Of The So-Called Open House Procedure
Conclusion Of Non-Exclusive Discount Agreements According To §130A Para.8 Sgb V For Various Active Ingredients/Combinations With The Possibility Of Conclusion At Any Time Within The Framework Of The So-Called Open House Procedure
Conclusion Of A Non-Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For Medicinal Products Containing The Active Ingredient Erythropoietin (Atc Code B03Xa01).
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb V) For The Active Ingredient Erythropoietin (Exclusively Epoetin Zeta), (Obo), Atc B03Xa01 For The Period 01.12.2024 - 30.11.2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb V) For The Active Ingredient Erythropoietin (Exclusively Epoetin Zeta), (Obo), Atc B03Xa01 For The Period 01.12.2024 - 30.11.2026
Medicines Containing The Active Ingredient Erythropoietin (Atc: B03Xa01 - In The Strength Over 10,000 Iu Per Dosage Unit)
Medicines Containing The Active Ingredient Erythropoietin (Atc: B03Xa01 - In The Strength Up To 10,000 Iu Per Dosage Unit)
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Erythropoietin (B03Xa01) Within The Framework Of A So-Called Open-House Model.
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Erythropoietin (B03Xa01) Within The Framework Of A So-Called Open-House Model.
Conclusion Not Exclusive Of Am Discount Agreement According To Section 130A Paragraph 8 Sgb V By Means Of An Oh Model For Ws Epoetin Alfa (Genetically Engineered Human Erythropoietin - Restriction To Packs With Doses Up To 10,000 Iu)
Bidding For The Purchase Of 2 Medicine Items As Follows: 1. Erythropoietin Alfa Sterile Sol 40,000 Iu./Pre-Filled Syringe, Quantity 1,200 Syringe, 2. Hydroxyurea 500 Mg. Capsule, Quantity 180,000 Capsules, By Means Of Electronic Bidding.
Tenders by Country